TITLE:
Melanoma: Surgery Subsequent to PDT—Is It Worth Doing? A 10-Year Pilot Trial Using Chlorin-Type Photosensitizer Bremachlorin®
AUTHORS:
Evgeniy I. Volkov, Andrei V. Reshetnickov, Harrie Vink
KEYWORDS:
Melanoma, Skin, PDT, Radahlorin, Radachlorin, Bremachlorin, Photochlorin, Laser, Cancer
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.8 No.10,
October
31,
2017
ABSTRACT: Bremachlorin®, also known as “Radachlorin®” and Photochlorin, a composition of 3 chlorophyll a derivatives in an aqueous
solution [1], was initially introduced into the Russian and South Korean
Pharmacopoeias with the corresponding marketing authorizations received in 2006
and 2008, on the basal cell skin carcinoma PDT protocol. Phase I-II clinical
trials led in 2002-2005 showed no side effects, a good tolerability by patients
and a high clinical anti-tumor efficacy. Further studies described in the
present paper were fulfilled in accordance with a skin melanoma PDT + surgery combined technique protocol in 2006-2016.
Resulting from the present trial, up to the 100% complete responses were
achieved after resection and plastic surgery following PDT, with no melanoma
regrowth or metastases during 5 and 10-year observation periods. Conducting PDT
one day prior to tumor dissection can guarantee to meet the ablastics principles
at the subsequent surgery. At the same time, the PDT + surgery protocol can allow for dissecting the tumor with less distance
from its edge, which seems to be important for the face localizations of
tumors.